BLCM Bellicum Pharmaceuticals Inc.

-0.15  -5%
Previous Close 3.21
Open 3.24
Price To Book 1.97
Market Cap 135620911
Shares 44,320,559
Volume 457,981
Short Ratio
Av. Daily Volume 380,170

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 paediatric top-line data due 2Q 2019.
BPX-501 Rivo-cel
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 1 initial data released December 14, 2018 at ESMO noted 2/6 patients had tumor shrinkage >20%. Further data due 1H and 2H 2019.
Pancreatic cancer
Phase 1/2 commenced March 2017. Initial data 2019.
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer
Phase 2/3 trial to be initiated late-2018/ early-2019.
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)

Latest News

  1. Bellicum Pharmaceuticals to Participate in Jefferies 6th Annual IO Cell Therapy Summit
  2. Edited Transcript of BLCM earnings conference call or presentation 12-Mar-19 9:00pm GMT
  3. Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2018
  4. Bellicum Pharmaceuticals Q4 Earnings Preview
  5. Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call and Webcast on Tuesday, March 12, 2019
  6. Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Projections Moving into 2019
  7. How Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Could Add Value To Your Portfolio
  8. Aratana Therapeutics (PETX) in Focus: Stock Moves 6.8% Higher
  9. Bellicum Pharmaceuticals Enters Oversold Territory
  10. Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
  11. Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
  12. Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
  13. Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer
  14. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  15. Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel
  16. Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
  17. Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018
  18. Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  19. Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
  20. Before You Buy Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), Consider Its Volatility